Oxford Immunotec Global PLC (OXFD) VP Elizabeth M. Keiley Sells 4,085 Shares

Oxford Immunotec Global PLC (NASDAQ:OXFD) VP Elizabeth M. Keiley sold 4,085 shares of the stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $15.01, for a total transaction of $61,315.85. Following the sale, the vice president now owns 25,393 shares of the company’s stock, valued at approximately $381,148.93. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Oxford Immunotec Global PLC (NASDAQ OXFD) traded down 0.79% during midday trading on Friday, reaching $15.01. 109,375 shares of the company’s stock traded hands. The company’s market cap is $344.12 million. Oxford Immunotec Global PLC has a 52-week low of $7.73 and a 52-week high of $16.13. The stock has a 50-day moving average of $14.49 and a 200 day moving average of $14.57.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its earnings results on Tuesday, May 2nd. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.01. The company had revenue of $21.51 million during the quarter, compared to the consensus estimate of $21.17 million. Oxford Immunotec Global PLC had a negative return on equity of 31.48% and a negative net margin of 25.83%. On average, analysts anticipate that Oxford Immunotec Global PLC will post ($1.09) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

COPYRIGHT VIOLATION WARNING: “Oxford Immunotec Global PLC (OXFD) VP Elizabeth M. Keiley Sells 4,085 Shares” was originally published by sleekmoney and is the property of of sleekmoney. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://sleekmoney.com/oxford-immunotec-global-plc-oxfd-vp-elizabeth-m-keiley-sells-4085-shares/1916511.html.

OXFD has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. BTIG Research reiterated a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Thursday, May 4th. Finally, ValuEngine upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $18.00.

Several hedge funds and other institutional investors have recently bought and sold shares of OXFD. Quantitative Systematic Strategies LLC bought a new position in Oxford Immunotec Global PLC during the first quarter worth approximately $156,000. Parkwood LLC bought a new position in Oxford Immunotec Global PLC during the first quarter worth approximately $176,000. American International Group Inc. boosted its position in Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after buying an additional 904 shares during the period. Nationwide Fund Advisors boosted its position in Oxford Immunotec Global PLC by 1.9% in the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock worth $213,000 after buying an additional 254 shares during the period. Finally, TFS Capital LLC boosted its position in Oxford Immunotec Global PLC by 19.8% in the first quarter. TFS Capital LLC now owns 14,125 shares of the company’s stock worth $219,000 after buying an additional 2,337 shares during the period. 87.63% of the stock is owned by hedge funds and other institutional investors.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/oxford-immunotec-global-plc-oxfd-vp-elizabeth-m-keiley-sells-4085-shares/1916511.html

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *